FDA Approves First-of-Its-Kind Device for Locally Advanced Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved Optune Pax, a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. This non-invasive therapy utilizes Tumor Treating Fields (TTFields) to disrupt cancer cell division and has shown promising results in extending overall survival when combined with standard chemotherapy.
How Optune Pax Works
Optune Pax, developed by Novocure, delivers TTFields – alternating electrical fields – to the abdomen via electrically insulated adhesive patches connected to a portable device. These fields interfere with the rapid division of cancer cells, hindering their multiplication while minimizing harm to healthy tissues. The device is designed for continuous use during daily activities, and its therapeutic parameters are preset, requiring no adjustments by clinicians or patients .
Clinical Trial Results
The FDA’s approval is based on data from the pivotal Phase III clinical trial, PANOVA-3. The study involved adult patients with locally advanced pancreatic cancer who received standard chemotherapy with gemcitabine and nab-paclitaxel (GnP), with or without the addition of TTFields . Results demonstrated that adding TTFields to the GnP regimen prolonged overall survival by approximately two months compared to chemotherapy alone .
Significance of the Approval
“Pancreatic cancer is one of the most challenging cancers to treat, and patients have long needed new therapeutic options,” said Michelle Tarver, M.D., Ph.D., director of the FDA’s Center for Devices and Radiological Health . This approval represents a novel, non-invasive approach that can be integrated into patients’ daily lives, expanding access to cancer care beyond traditional clinical settings.
According to the National Cancer Institute, pancreatic cancer was expected to result in approximately 67,440 new diagnoses and 51,980 deaths in the U.S. In 2025 .
Side Effects
The most commonly reported side effect associated with Optune Pax was localized skin reactions at the sites where the transducer arrays contact the skin . The treatment led to a statistically significant increase in overall survival, without adding systemic adverse effects to those usually associated with existing therapies .
Looking Ahead
The approval of Optune Pax marks an important milestone in the treatment of locally advanced pancreatic cancer, offering a new option for patients who have limited therapeutic choices. It is the first treatment to be FDA approved in nearly 30 years for this specific condition . Further research and innovation are crucial to continue improving survival rates and quality of life for individuals battling this challenging disease.